ReviewChallenges to production of antibodies in bacteria and yeast
Section snippets
Antibody production in bacteria
Bacteria are very attractive for use in recombinant protein production because of their fast growth, ease of manipulation, relatively well-known information and much lower antibody production costs. A number of bacterial hosts (e.g., E. coli, Corynebacterium glutamicum, Bacillus megaterium, Pseudomonas putida) have been utilized for recombinant protein productions (7), and the recent progress made in the production of various antibodies using those bacterial hosts is summarized in Table 1.
Antibody production in yeast
Antibodies originate in the immune cells of animals, thus eukaryotic hosts are preferable for producing recombinant antibodies than prokaryotes. Yeast is a eukaryotic host, but has also several beneficial properties that are comparable to prokaryotic microbial hosts (e.g., fast growth, ease of genetic manipulation, low cultivation cost). In addition, the presence of its own glycosylation machinery makes yeast more attractive than prokaryotes for the production of functional antibodies, despite
CONCLUSIONS AND FURTHER PERSPECTIVE
As of 2014, 32 antibodies are being marketed, and more than 200 antibodies are being evaluated in clinical studies. Given this explosive growth of therapeutic antibodies, the finding of new antibodies is no longer an extraordinary issue in most of the cases. Rather, the development of processes for their economic production is becoming an ever more important issue. Although there have been many successful achievements in engineering of bacterial and yeast hosts as described above, the drive to
Acknowledgments
Ki Jun Jeong expresses his appreciation to the Society for Biotechnology, Japan, which awarded him the Young Asian Biotechnologist Prize in 2014. This research was supported by the Intelligent Synthetic Biology Center of Global Frontier Project (Grant no. 2014M3A6A8066443) funded by the Ministry of Science, ICT, and Future Planning (MISP).
References (87)
- et al.
Generation and characterization of inhibitory nanobodies towards thrombin activatable fibrinolysis inhibitor
J. Thromb. Haemost.
(2010) - et al.
Therapeutic antibodies: market considerations, disease targets and bioprocessing
Int. J. Pharm.
(2013) Process economics of industrial monoclonal antibody manufacture
J. Chromatogr. B Anal. Technol. Biomed. Life Sci.
(2007)- et al.
The periplasmic Escherichia coli peptidylprolyl cis,trans-isomerase FkpA. I. Increased functional expression of antibody fragments with and without cis-prolines
J. Biol. Chem.
(2000) - et al.
Effects of cytoplasmic and periplasmic chaperones on secretory production of single-chain Fv antibody in Escherichia coli
J. Biosci. Bioeng.
(2011) - et al.
Engineering production of functional scFv antibody in E. coli by co-expressing the molecule chaperone Skp
Front. Cell Infect. Microbiol.
(2013) - et al.
Functional expression of single-chain Fv antibody in the cytoplasm of Escherichia coli by thioredoxin fusion and co-expression of molecular chaperones
Protein Expr. Purif.
(2010) - et al.
Production of correctly folded Fab antibody fragment in the cytoplasm of Escherichia coli trxB gor mutants via the coexpression of molecular chaperones
Protein Expr. Purif.
(2001) - et al.
Escherichia coli maltose-binding protein as a molecular chaperone for recombinant intracellular cytoplasmic single-chain antibodies
J. Mol. Biol.
(2001) - et al.
Development of a plasmid display system with an Oct-1 DNA-binding domain suitable for in vitro screening of engineered proteins
J. Biosci. Bioeng.
(2013)